25

PHAXIAM Therapeutics S.A.

Date: March 1, 2024

/s/ Eric Soyer

Eric Soyer

Deputy Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

25 1 d768090d25.htm 25 25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR

REGISTRATION UNDER SECTION 12(b) OF THE

SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-38281

PHAXIAM Therapeutics S.A.

The Nasdaq Capital Market

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)


France		Not applicable
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

60 Avenue Rockefeller Lyon, France		69008
(Address of Principal Executive Offices)		(Zip code)

American Depositary Shares, each representing one ordinary share, nominal value €1.00 per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐	17 CFR 240.12d2-2(a)(1)

☐	17 CFR 240.12d2-2(a)(2)

☐	17 CFR 240.12d2-2(a)(3)

☐	17 CFR 240.12d2-2(a)(4)

☐	Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

☒	Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, PHAXIAM Therapeutics S.A. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

SEC Form 25 filed by PHAXIAM Therapeutics S.A..